Table 5 Comparison of standardized mortality ratios with other studies
From: Mortality among British Columbians testing for hepatitis C antibody
Author | Country | Â | All cause SMR (95% CI) | Liver related SMR (95% CI) | Drug related SMR (95% CI) |
|---|---|---|---|---|---|
Amin [12] (2006) | Australia | HCV mono-infected | 3.1 (3.0-3.2) | 16.8 (15.4-18.3) | 19.3 (18.1-20.5) |
HCV/HBV co-infected | 5.6 (4.8-6.6) | 32.9 (23.1-46.7) | 24.7 (18.2-33.5) | ||
Duberg [13] (2008) | Sweden | HCV mono-infected | 5.8 (5.6-6.0) | 35.5 (32.9-38.3) | 20.7 (18.9-22.7) |
HCV/HBV co-infected | 8.5 (7.3-9.8) | 46.2 (31.5-62.3) | 27.6 (19.6-39.6) | ||
McDonald [15] (2008) | Scotland | HCV mono-infected | 4.9 (4.6-5.1) | 20.0 (17.9-22.2) | 23.5 (21.3-25.7) |
HCV/HIV co-infected | 32.9 (29.2-37.0) | 34.8 (23.3-50.0) | 36.6 (25.2-51.4) | ||
Yu (2012) | Canada | All HCV-infected | 4.8 (4.6-5.0) | 23.7 (21.9-25.7) | 20.7 (19.1-22.5) |
REAC | 4.7 (4.5-4.9) | 23.9 (22.0-26.0) | 19.9 (18.3-21.7) | ||
SERO | 10.1 (8.4-12.1) | 14.8 (6.4-29.1) | 36.7 (27.1-48.5) |